Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Return on Assets (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed Return on Assets for 4 consecutive years, with 0.22% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Assets rose 26.0% year-over-year to 0.22%, compared with a TTM value of 0.22% through Sep 2025, up 26.0%, and an annual FY2024 reading of 0.74%, up 68.0% over the prior year.
  • Return on Assets was 0.22% for Q3 2025 at Summit Therapeutics, up from 0.36% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.04% in Q4 2022 and bottomed at 2.89% in Q4 2023.
  • Average Return on Assets over 4 years is 0.95%, with a median of 0.5% recorded in 2024.
  • The sharpest move saw Return on Assets plummeted -285bps in 2023, then surged 239bps in 2024.
  • Year by year, Return on Assets stood at 0.04% in 2022, then tumbled by -6898bps to 2.89% in 2023, then surged by 83bps to 0.5% in 2024, then surged by 55bps to 0.22% in 2025.
  • Business Quant data shows Return on Assets for SMMT at 0.22% in Q3 2025, 0.36% in Q2 2025, and 0.46% in Q1 2025.